Pharma ad‑tech surge threatens legacy DSPs and SSPs
Pharma advertisers are channeling billions into specialized ad‑tech platforms like DeepIntent, pulling spend from traditional demand‑side and supply‑side exchanges. The shift, driven by tighter FDA rules and privacy demands, forces legacy DSPs and SSPs to rethink their strategies for a highly regulated vertical.